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Letters to the Editor
A NEW ONSET PARANOID PSYCHOSIS ASSOCIATED WITH FLUOXETINE AND
BUPROPION: A CASE REPORT
To th e editor : Bupropion, a uni cyclic aminoke to ne, has a chem ica l st ru ctur e that is
uniqu e a mong a ntide press a nts (I ). Bupropion a lso has a relatively favor able side effec t profi le
(2); but occasiona l seve re side effec ts, including del irium a nd psychoses, have been report ed
(2- 11). We pr esent a patient who appear ed to hav e a bupropion-induced psycho tic disord er ,
with a lmost exclusively delu sion al sym ptoma tology.
Ms. A was a 45 yea r old sing le Afri can -Am eri can mother of two when she was seen in the
outpatient psychi atric clinic for depression. Her medi cal hist ory was significant for obesity,
diabetes type 2, and ost eoarthritis, for whi ch sh e took glyburide 5 mg/d ay and ibuprofen 1600
mg/day. In her la te 30's, Ms . A had her uterus rem oved seco ndary to uterine fibroids ; she
subsequent ly had very mi ld postmenopausal sym ptoms, whi ch last ed for less than a year. Her
med ica l condi tion was stable, with blood glucose ran gin g betw een 150 - 200 mg/d l. Her
hemoglobin Al c was between 6.4 and 9.3%. Blood coun t, elec tro lytes , TSH, 1'4, urinalysis, and
liver function tests were normal. Her HDL wer e 34 mg/d l (normal ran ge 35 a nd high er) and
choles te rollH DL rat io was 5.38 (normal ran ge 0.00-4.44) .
Ms. A had no pr evious history of psychiatric inpatient tr eatment , suicide atte mpt, man ia,
psychosis or confus ion, and no history of drug or alcoho l use. Her family history was significant
for schizophrenia in her old er sist er, who had died of myocardial infar cti on, a nd a hist ory of
depression in th e younger sist er, who was taking an unknown psychi atric medi cation .
Ms. A had graduated from high school, and for more than 20 yea rs wor ked as a nursing
assista n t. She had been married a nd divor ced twice , has two child ren, and lives with her
youngest daught er. Ms . A's first depressiv e episode occurred at th e age of 43; apparent ly not
provoked by any external or physical stressor. Her condition had gr ad ua lly det eri or at ed to th e
point that sh e had been unable to work , and had to q uit her job. Most of th e tim e she rema ined
in bed , and became socia lly wit hd rawn, whi ch was com ple te ly different from her premorbi d
per sonalit y. Aft er approxima tely ten months of depressive sym ptoms, Ms. A was referred by
her internist to th e outpatient psych iatric clinic. According to th e pati ent 's medi cal record, she
had demonstra ted depress ed mood, depressive cognit ion, veget ative symptom s of dep ression,
motor retarda tion, an d impai red con centration. Sh e was tr eat ed in iti all y with fluoxctine 20 mg
per day, with gradual titration to 60 mg/day over th e next 8 weeks. Ms. A respond ed to th e
high er dos e with sign ificant improvem ent in her mood, a llevia tion of mot or re ta rda tion ,
improvem ent in her cognition, a nd significant improvem ent in her vege ta t ive sym ptoms as
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well. O ver the next seve ra l months, whil e she cont inue d to tak e 60 mg of fiuoxetine daily, Ms.
A did well. Sh e became more socia l, was helping her family as she had don e before the
depression, and even returned to work .
Aft er five months of treatmen t with 60 mg of fluoxetine dai ly, Ms. A had sto pped the
medi cation , and dropped out of treat ment. She remained asymptomatic for a no ther four
months, when she red evelop ed depressive sym pto ms, a nd was seen ag a in a t our outpat ient
clinic. On exa m Ms. A had depress ed mood , psychomotor retardation , low ene r!:,')" level , seve re
anhedonia , initial a nd middle in somnia, hop elessn ess, helplessn ess, self - depreciati on , a nd
ruminative th ou ght s. Her cognit ive exam was normal , a nd she had no psychotic sym pto ms .
Flu oxetine was rest art ed and titrat ed to 80 mg/day over th e next 2 mo nt hs . She remained on
80 mg/d ay for 5 weeks, without significa nt improvem ent , a t whi ch tim e bupro pion SR was
added to her fluoxetine regim en , at 50 mg/d ay, Aft er 3 days bupropion was incr eased to 100
mg/day. On th e 3rd day of treatment with bupropion 100 mg a day, Ms. A devel oped ideas tha t
peopl e were talking a bout her, st ra ng ers on th e st ree ts were wat ching her, a nd she felt
reluctant to leave her hou se. On th e 7'h day of bupropion tr ea tment Ms. A was re-evalu a ted
as an outpatient. H er exa m at th at tim e revealed no significan t impairment in orie nta tion,
conce n tra t ion, or m emory. Sh e had delusion al ideas of referen ce (as above) and no insight in to
her psychotic symptoms. She rep orted her mood to be better, a nd her affec t was less
depressed, with no hop elessn ess, or helplessn ess. Her e ne rgy was a lso bett er, as was her
appe tite . No manic sym ptoms were obs erved . The bupropion was di scontinued , a nd Ms. A was
given risperidone 1.5 mg bid . She took only on e do se, th en s topped th e a ntipsychot ic
m edi cation secondary to severe seda t ion. O ver the next 7 days, her psychotic symptoms
resolved comple tely, but she began to experience a n exace rba tion of her dep ress ive sym ptoms.
Three week s later her fluoxetine was stopped, and Ms. A was switched to ve nla fax ine. O n
follow up aft er 3 months , Ms . A had mild depressive sympto ms, no psychoti c symptoms, an d
no cog n itive impairment.
The mech anism of acti on of buprop ion is not well unders tood ( I); however, it is beli eved
th at th e an tide pressa nt effec t, an d possibly some sid e effec ts, a re du e to nor ep inephrine
turnover, and to less er ex te nt, dopamin e reuptak e blockad e ( 1,2) . T here have been severa l
case reports of appa re nt bupropion-associat ed psychosis (2- 11), however , most of th e patie nt s
who developed psych osis whil e taking bu pr op ion had a history of psychosis pri or to buprop ion
treatment. Som e of th ese rep orts describe not only pathology of th ou ght pro cesses, and
perceptual di sturbances, but also definit e cog nitive impairment with clo ude d consciousness .
We were abl e to identify only 3 report s of psychotic sym pto ms in th e abse nce of cog nit ive
im pa irme nt in non-predi sposed ind ividuals followin g buprop ion treatment (2 cases of hallu-
cina t ions, and one cas e of delusion s and hallu cin ation s) (9- 11). T o ou r knowled ge, no reports
described pure delusional psychosis without perceptual di sturban ces. Addi t iona lly, all of the
reports of bupropion-induced psychosis a nd bupropion-induced delirium involved daily doses in
th e range of 300 mg a nd a bove (2- 10) . In our patient , th e maximum dose d id not exceed 100
mg/d ay of bupropion SR.
Bupropion undergoes extensive hep at ic metaboli sm , mainly through th e CYP 450 IIB6
a nd IIIA 3/4 syst ems (15); th e latter of whi ch is known to be suppressed by fiuoxetine ( 14,15).
Bupropion docs not appear to be metabolized by IID 6 isoen zym es; however, th ere a rc some
dat a th at bupropion and it s metabolites may in hibi t IID 6 ( 14), whi ch is a secon dary met ab olic
pathway for fluoxetine. Bupropion met ab olites may be eleva ted in people wit h hepa tic di sease
a nd in th e elde rly, whi ch ma y be contributory to side effec ts ( 10, 15). In our pa t ient , th e
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significa nt improvem ent in he r moo d bega n afte r several days of treatment wit h bupropion, at
approxima te ly th e same ti me th at she s tarte d experienc ing de lus ions. Both her mood
im provement , as well as psychotic sym ptoms, migh t be a tt r ibuted to an inc reased level of
bupropion met abolites.
Alte rna tively, th e ph en om ena of dru g-associated delusions might be expla ined by ser o-
ton ergic mecha nisms . Flu oxetine inc reases ve n tra l stria ta l serotoni n ( 17), stimulating 5-HT3
receptor-me d ia te d dopam in e release in th e ventral stria ta l region, wh ich may lead to psych osis
( 18). Unde rle ider a nd Pechnick ( 19), in reviewi ng th e mecha nisms of act ion of hall ucinogens,
co ncl ude d th at th ese age nts work throu gh effects a t 5-HT2 receptor s. However , Pie rce and
Peroutka (20) sugges te d th at ac tion a t 5-I-IT IC, a nd not 5-1-1'1'2 receptor s, may account for th e
hallucin ogenic pr op erties. Am on g several report s d escribing Iluoxetine a nd psych oses, (18,2 1-
24) we were able to identify only one case of possibl e f1u oxetine-induced persecutory delusions
in a patient who did not have pr evious hist or y of psych osis (20); as we ll as 3 re ports of visual
hallucinosis (22-24) . One of those patient s was a lso taking L-dopa, a nd ano t he r develop ed
visua l hallucinosis aft er dextromethorphan had been adde d to her regimen. Althou gh it is
pos sibl e to attribut e Ms. A's psychotic sym ptoms to eleva te d level s of f1u oxetine, ca used by
bupropion-associat cd 2D 6 inhibit ion , we beli eve that it is unlikely, s ince th e CYPIID6 system
is onl y a minor pathway for f1uoxetine ( 13).
One other possible expla na tion for th e development of psych oti c sym ptoms in Ms. A
wou ld be a so-ca lle d "sc hizoa ffcc tive evolut ion" in th e course of her a ffec tive illness . Although
Ms. A had a fa m ily hist or y of schizophrenia a nd de press ion, we th ink th is is ext rem ely un likely,
du e to th e sho rt sym ptomat ic per iod of th e delusion s (a bo ut 8 days), t hei r di sappea ra nce
wi t ho ut specific an tipsycho tic treatme nt , th e obvious temporal rela tionsh ip wit h t he initiation
of bupropion tr ea t me nt , a nd th e lack of negative sympto ms be tween her de pressive episodes .
Of add it ional in terest was Ms. A's initial res po nse to Iluoxet ine, but lack of response to
th e sa me medi cation wh en it was rest a rt ed , eve n at incr eased dose . The development of
tol erance to th e therapeutic effec ts of SSRI 's, whi ch Goodnick a nd Go lds tei n (25) hav e te rmed
" ne uro phys iologica l tole ran ce" , is a well-known ph en om en a , an d has be en reported elsewh er e
(25 -3 1). Fava e t a l (26) in th eir s tudy of re-initiation of ant ide pressan t t reat men t in patient s
wh o pr eviously responded to fluoxctine, but lat er we re switc he d to placeb o and relapse d, found
that 38% of th e patients did not respond to th e re -init ia t ion of fl uoxe tin e. Mi ch elson e t a l (29 )
rep or ted th at Iluox e tin e occasiona lly lost efficacy afte r 9 months of co ntinued t reatment ,
foll owin g res po nse to 12-14 week s of initial treatment. Fava e t a I., (30) rep ort ed t ha t rela pse
or recurren ce of depressive sym pto ms occurr ing in pa tie nts receivin g conti nua tion or main-
ten an ce th erapy with Huoxet in e 20 rug/d ay, ca n be tr ea ted effectivel y by increasing the dos e
to 40 rug/day. Conversely, Cain (31) postulating that overmedi cation with Iluoxet ine might
a ppear as a response failure, report ed 4 patients who continue d to det eri or at e wh en their dose
of f1uoxetine was raised, but that symptoms improved dram aticall y during sys te ma tic tri al s of
lowe r doses. Ca in noted th at higher doses of Iluoxetine may co rre la te with high plasm a
co nce n tra tion of norfluox ct in e, th e ac t ive metabolite of fluoxetine, wh ich was sometimes
as socia te d with a poor clinical response. (3 1).
The m ech anism of this loss of efficacy of SSRI's, a nd flu ox et inc in particul a r, rema ins
unclear. One hypothesis sugges ts th at long-t er m trea t ment with Iluoxet iue may ca use a
relative dop amine deficien cy, whi ch may resp ond to tr eatment wit h pos tsy na ptic do pamine
agonists (33). Our case may lend support to this th eory, surround ing th e fac t th a t Ms. A
develop ed delusion al ideas, but a lso had rep ort ed some imp roveme nt in her mood.
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One final possible explana t ion for Ms. A' s treatment resist an ce may be th e cont ribut ion
of her medi cal cond itions, diab et es in particul a r. Her diab et es was not well controlled, based
on th e hem oglobin Al c level, as well as incr eased cholesterollH DL and low HDL. Howeve r, th c
rest of her laboratory exa ms wer e normal , so it see ms unlikely th at her ini tia l lack of response
to fluoxetine ma y be a tt r ibute d to her medi cal cond it ion. Also, th e re a re som e reports th at
fluoxetine has prov en effec t ive as an ant ide pressan t in th e tr eat ment of depression assoc ia ted
with se rous physical illn esses, including diab et es (34).
\Ve pr esent th e case of a 45 yea r old wom an with depression unresponsive to fluoxet ine,
whos e depression responded to th e adj unc tive addition of bupropion , but who developed fra nk
psychosi s soon aft er initiation of bupropion in low-moderate dose. We sugges t a cautious
approach in th e concurrent use of bupropion and substances that int erfere with its metabolism.
Vassili Ark adiev, MD
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